Pimavanserin


Selective 5-HT2A inverse agonist

The first FDA-approved drug for Parkinson disease psychosis; a selective 5-HT2A inverse agonist with no dopamine receptor activity.

Abstract

Pimavanserin (1-[(4-fluorophenyl)methyl]-1-[(1-methyl-4-piperidinyl)methyl]-3-{4-[(2-methylpropoxy)]phenyl}urea; CAS 706779-91-1; molecular formula C25H34FN3O2; molecular weight 427.56) is a selective 5-HT2A inverse agonist developed at ACADIA and approved by the FDA in 2016 under the trade name Nuplazid. Distinct among antipsychotics by absence of dopamine receptor activity: D2 affinity is greater than 1000 nM, with no clinically relevant binding. Selectivity is for 5-HT2A (Ki approximately 0.087 nM) over 5-HT2C (Ki approximately 0.4 nM, approximately 5-fold selective). The compound is a high-efficacy inverse agonist (not merely an antagonist), reducing constitutive 5-HT2A signaling below baseline. The dopaminergically clean profile is uniquely suited to Parkinson disease psychosis, where conventional antipsychotics’ D2 antagonism worsens motor symptoms; pimavanserin treats hallucinations and delusions without aggravating bradykinesia or rigidity. Plasma half-life is 57 hours for parent compound, 200 hours for active metabolite. Metabolism is via CYP3A4 and CYP3A5. The compound carries an FDA black-box warning for increased mortality in elderly dementia patients (a class warning for all antipsychotics). Used as the reference selective 5-HT2A inverse agonist.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph